PTC THERAPEUTICS, INC. - 8-K Filing
PTC Therapeutics reported Q2 revenue of $361M with Sephience driving growth and raised full-year product revenue guidance (Items: 2.02 Results of Operations and Financial Condition, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $PTCT